5054 Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results

V.Michalaki; S.Gennatas; C.Gennatas

首页> 外文期刊>European Journal of Cancer Supplements >5054 Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results

【24h】

5054 Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results

机译：5054曲妥珠单抗联合卡培他滨和多西他赛联合治疗转移性乳腺癌的一线治疗的安全性和有效性：II期结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
V.Michalaki; S.Gennatas; C.Gennatas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 5054 Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results [J] . V.Michalaki, S.Gennatas, C.Gennatas European Journal of Cancer Supplements . 2009,第2期

机译：5054曲妥珠单抗联合卡培他滨和多西他赛联合治疗转移性乳腺癌的一线治疗的安全性和有效性：II期结果
2. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. [J] . Hamberg P, Bos MM, Braun HJ, Clinical breast cancer . 2011,第2期

机译：II期随机研究比较了曲妥珠单抗和多西他赛联合治疗与序贯治疗的曲妥珠单抗联合多西他赛在HER2 +转移性乳腺癌患者一线化疗中的疗效和安全性：HERTAX试验。
3. TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：TBCRC049：II期非随机性研究，以评估Tucatinib和Trastuzumab和Capecitabine的组合的安全性和功效，用于治疗Her2阳性乳腺癌TBCRC049中的百分声膜转移：II期非随机性研究，以评估安全性和疗效 Tucatinib和Trastuzumab和Capecitabine的组合治疗HER2阳性乳腺癌中的百分症转移
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer [O] . Edith A Perez, Sara A Hurvitz, Lukas C Amler, 2014

机译：TDM4450g中一线曲妥珠单抗艾坦相比曲妥珠单抗加多西他赛的疗效与HER2表达之间的关系：一项先前未经治疗的HER2阳性转移性乳腺癌患者的II期随机研究
7. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer [O] . Edith A Perez, Sara A Hurvitz, Lukas C Amler, 2014

机译：TDM4450g中一线曲妥珠单抗艾坦相比曲妥珠单抗加多西他赛的疗效与HER2表达之间的关系：一项先前未经治疗的HER2阳性转移性乳腺癌患者的II期随机研究

5054 Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results

著录项

相似文献

相关主题

期刊订阅